Celldex Therapeutics, Inc. (CLDX) is a leading American biopharmaceutical company focusing on the development and commercialization of several immunotherapy technologies. It specifically targets the most challenging diseases like cancer. The company is headquartered in Hampton, New Jersey, and is publicly traded under the symbol "CLDX" on the NASDAQ stock exchange.
Since its establishment in 1983, Celldex has demonstrated a strong commitment to advancing science and revolutionizing treatment protocols to vastly improve patients' lives. The company's pipeline comprises several clinical-stage, pre-clinical, and research-stage candidates, all directed at various cancer types and other severe health conditions.
Celldex Therapeutics, Inc. (CLDX) has repeatedly distinguished itself by its breakthrough discoveries and the development of novel therapies. For example, their Precigen Triplebody™ candidates, CDX-0159, CDX-1140, and CDX-301, are promising treatments for allergic diseases, multiple cancers, and vaccination enhancement strategies, respectively. These products have generated attention in the biopharma industry for their unique and targeted approaches.
The company has a very strong scientific and managerial team, with expert scientists, advanced researchers, and industry veterans dedicated to bringing new therapies from bench to bedside. They prioritize patient welfare above all, working aggressively to shorten the time it takes for new discoveries to become available and affordable treatments.
Celldex Therapeutics, Inc. (CLDX) is keenly aware of the responsibilities that come with being a pioneering biopharma enterprise. As such, it remains highly committed to rigorous research, ethical testing practices, and regulatory compliance. It also actively collaborates with other industry leaders and research institutions to stimulate innovation and expedite the development of life-saving therapies.
Financially, Celldex Therapeutics, Inc. (CLDX) has shown impressive resilience and growth despite the volatility and risk traditionally associated with the biopharma industry. It continues to attract investment primarily due to its innovative product pipeline and the promising nature of its ongoing clinical trials.
In conclusion, Celldex Therapeutics, Inc. (CLDX) embodies the scientific rigor, patient focus, and innovative spirit that define the best of the biopharma industry. It continues to push the boundaries of immunotherapy, committed to revolutionizing treatment options for patients battling cancer and other life-threatening diseases.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
FMR LLC and Abigail P. Johnson have disclosed a 10.7% beneficial ownership stake in Celldex Therapeutics Inc. as of September 30, 2026. This information was detailed in an Amendment No. 7 to their Schedule 13G filing with the SEC on October 6, 2026. Both entities reported owning 8,411,905.03 shares of Celldex Therapeutics common stock.
Celldex Therapeutics, Inc. (CLDX) is drawing market attention after its barzolvolimab studies in chronic spontaneous urticaria met primary and key secondary endpoints. This development highlights the company's operating priorities and its position within the Healthcare Stocks sector. Investors are now focused on consistent execution and how these positive clinical results translate into sustained operational success and customer response.
Celldex Therapeutics (CLDX) recently announced positive Phase 3 trial results for its lead asset, barzolvolimab, in chronic spontaneous urticaria, demonstrating best-in-disease efficacy and high rates of complete response. While the company has a strong cash balance and a broad pipeline, it faces a heavy burn rate with widening net losses and a BLA submission not expected until 2027. The market is divided on CLDX, reflecting both the clinical promise of barzolvolimab and the financial challenges and mixed results from other programs.